Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tenidap--a new antiarthritic agent

P M Brooks1

  • 1University of New South Wales, St. Vincent's Hospital, Darlinghurst, Australia.

Agents and Actions. Supplements
|January 1, 1993
PubMed
Summary

Tenidap sodium, a novel cytokine inhibitor, shows promise in treating rheumatoid arthritis (RA) and osteoarthritis (OA). Clinical trial results are anticipated to confirm its disease-modifying and symptomatic relief capabilities in these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Australia needs an Ombudsman or Office for Research Integrity.

Internal medicine journal·2016
Same author

The management of rheumatoid arthritis.

The Australian journal of physiotherapy·2014
Same author

The patient is the teacher: ambulatory patient-centred student-based interprofessional education where the patient is the teacher who improves patient care outcomes.

Internal medicine journal·2013
Same author

The clinical significance of indomethacin-probenecid interaction.

British journal of clinical pharmacology·2012
Same author

The effect of frusemide on indomethacin plasma levels.

British journal of clinical pharmacology·2012
Same author

Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?

Inflammopharmacology·2008

Area of Science:

  • Immunology and Pharmacology
  • Rheumatology

Background:

  • Tenidap sodium is identified as a novel cytokine inhibitor.
  • Preliminary research indicates potential disease-modifying and symptomatic benefits for rheumatoid arthritis (RA).

Purpose of the Study:

  • To evaluate the efficacy and safety of tenidap sodium in patients with RA and osteoarthritis (OA).

Main Methods:

  • Clinical trials were conducted to assess the therapeutic effects of tenidap sodium.
  • Dosage-response was investigated, noting effectiveness in OA at lower concentrations than in RA.

Main Results:

  • Early studies suggest tenidap sodium offers both symptomatic relief and a disease-modifying profile in RA.
  • The drug demonstrates efficacy in OA treatment, requiring a significantly lower dose.

Conclusions:

  • Tenidap sodium presents a potential new therapeutic agent for inflammatory joint diseases.
  • Further clinical trial data on efficacy and safety in RA and OA are eagerly awaited.

Related Experiment Videos